Research Grade Inbakicept|Inbakicept（研究用级别）(靶标：Inbakicept融合蛋白)
- 货号：RB9THW541026
- 价格：面议
- 点击：222
产品介绍
产品参数
| 形态 | Liquid |
|---|---|
| 抗体亚型 | Fusion - [IL15RA (interleukin 15 receptor subunit |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 浓度 | 1mg/ml |
| 内毒素水平 | Please contact the lab for this information. |
| 应用 | ELISA, Functional assay, Research in vivo |
| 种属反应性 | Human |
| 靶标 | IL15, IL-15, Interleukin-15 |
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 表达系统 | Mammalian Cells |
| 登录号 | P40933 |
| 背景信息 | Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells. • Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer., PMID:35660135 • Interleukin 15: A key cytokine for immunotherapy., PMID:27325459 • IL-15 in the Combination Immunotherapy of Cancer., PMID:32508818 • IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells., PMID:31277710 • Interleukin-15 in autoimmunity., PMID:32919253 • Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers., PMID:39604730 • An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery., PMID:36165896 • IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease., PMID:32051586 • Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect in vivo., PMID:37818365 • Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy., PMID:34797911 |
| 别名 | ALT-803(=inbakiceptINN11029([IL15RA]2-Fc)incomplex1:2withnogapendekinalfaINN11157(IL15D72)), [IL15RA]2-Fc, 2135939-52-3 |
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
相关产品: